IPCALAB.NS
Ipca Laboratories Limited [IPCALAB.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IPCALAB.NS Stock Summary
Top IPCALAB.NS Correlated Resources
IPCALAB.NS
Top 10 Correlated ETFs
IPCALAB.NS
Top 10 Correlated Stocks
IPCALAB.NS
In the News
IPCALAB.NS Financial details
Company Rating
Buy
Market Cap
198.62B
Income
5.25B
Revenue
60.22B
Book val./share
-
Cash/share
-
Dividend
4
Dividend %
0.51%
Employees
15.16K
Optionable
No
Shortable
Yes
Earnings
16 Feb 2023
P/E
37.87
Forward P/E
6.37
PEG
-7.01
P/S
3.3
P/B
3.44
P/C
-
P/FCF
-
Quick Ratio
1.05
Current Ratio
3.29
Debt / Equity
-
LT Debt / Equity
0.08
-
-
EPS (TTM)
20.69
EPS next Y
122.89
EPS next Q
-
EPS this Y
-22.45%
EPS next Y
493.84%
EPS next 5Y
591.5%
EPS last 5Y
29.77%
Revenue last 5Y
12.7%
Revenue Q/Q
-3.43%
EPS Q/Q
-25.04%
-
-
-
-
SMA20
-7%
SMA50
-8.3%
SMA100
-13.75%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.11%
Gross Margin
64%
Oper. Margin
12%
Profit Margin
9%
Payout
-
Shs Outstand
253.7M
Shs Float
130.4M
-
-
-
-
Target Price
-
52W Range
767.5-1095.0
52W High
-28.51%
52W Low
+2.07%
RSI
33
Rel Volume
0.25
Avg Volume
290.95K
Volume
73.71K
Perf Week
-1.44%
Perf Month
-9.04%
Perf Quarter
-12.59%
Perf Half Y
-8.81%
-
-
-
-
Beta
0.151742
-
-
Volatility
3.67%, 30%
Prev Close
0.38%
Price
782.85
Change
-0.29%
IPCALAB.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
| Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 127.04 | 146.14 | 180.4 | 210.87 | 230.17 | |
| Net income per share | 9.49 | 17.61 | 23.99 | 45.01 | 34.91 | |
| Operating cash flow per share | 13.52 | 19.48 | 22.33 | 43.04 | 33.8 | |
| Free cash flow per share | 8.1 | 12.34 | 10.21 | 28.77 | 14.89 | |
| Cash per share | 8.66 | 14.71 | 16.54 | 29.91 | 58.89 | |
| Book value per share | 106.52 | 123.58 | 143.55 | 185.63 | 216.83 | |
| Tangible book value per share | 101.35 | 115.33 | 136.22 | 179.86 | 211.13 | |
| Share holders equity per share | 106.52 | 123.58 | 143.55 | 185.63 | 216.83 | |
| Interest debt per share | 25.79 | 19.13 | 20.44 | 10.82 | 32.17 | |
| Market cap | 83.93B | 122.88B | 175.91B | 241.09B | 269.93B | |
| Enterprise value | 88.71B | 124.72B | 180.34B | 242.08B | 275.25B | |
| P/E ratio | 35.06 | 27.62 | 29.01 | 21.15 | 30.53 | |
| Price to sales ratio | 2.62 | 3.33 | 3.86 | 4.51 | 4.63 | |
| POCF ratio | 24.6 | 24.96 | 31.18 | 22.12 | 31.53 | |
| PFCF ratio | 41.06 | 39.42 | 68.19 | 33.09 | 71.58 | |
| P/B Ratio | 3.12 | 3.94 | 4.85 | 5.13 | 4.92 | |
| PTB ratio | 3.12 | 3.94 | 4.85 | 5.13 | 4.92 | |
| EV to sales | 2.77 | 3.38 | 3.96 | 4.53 | 4.72 | |
| Enterprise value over EBITDA | 18.04 | 16.63 | 18.63 | 15.15 | 20.4 | |
| EV to operating cash flow | 26.01 | 25.34 | 31.96 | 22.21 | 32.15 | |
| EV to free cash flow | 43.4 | 40.01 | 69.9 | 33.23 | 72.99 | |
| Earnings yield | 0.03 | 0.04 | 0.03 | 0.05 | 0.03 | |
| Free cash flow yield | 0.02 | 0.03 | 0.01 | 0.03 | 0.01 | |
| Debt to equity | 0.53 | 0.45 | 0.45 | 0.29 | 0.38 | |
| Debt to assets | 0.35 | 0.31 | 0.31 | 0.22 | 0.27 | |
| Net debt to EBITDA | 0.97 | 0.25 | 0.46 | 0.06 | 0.39 | |
| Current ratio | 1.93 | 2.17 | 2.15 | 3.03 | 3.04 | |
| Interest coverage | 12.1 | 29.24 | 47.01 | 153.37 | 140.03 | |
| Income quality | 1.42 | 1.11 | 0.93 | 0.96 | 0.97 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0.06 | 0.03 | 0.2 | 0.09 | 0.11 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Intangibles to total assets | 0.03 | 0.05 | 0.04 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.4 | -0.37 | -0.54 | -0.33 | -0.56 | |
| Capex to revenue | -0.04 | -0.05 | -0.07 | -0.07 | -0.08 | |
| Capex to depreciation | -0.77 | -0.99 | -1.46 | -1.73 | -2.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 150.78 | 221.26 | 278.38 | 433.58 | 412.67 | |
| ROIC | 0.07 | 0.12 | 0.13 | 0.22 | 0.13 | |
| Return on tangible assets | 0.06 | 0.1 | 0.12 | 0.19 | 0.12 | |
| Graham Net | -30.5 | -19.99 | -21.34 | 8.01 | 13.84 | |
| Working capital | 9.38B | 12.8B | 15.29B | 23.04B | 29.91B | |
| Tangible asset value | 25.58B | 29.14B | 34.42B | 45.55B | 53.48B | |
| Net current asset value | 5.17B | 9.65B | 12.37B | 20.85B | 23.87B | |
| Invested capital | 0.23 | 0.15 | 0.14 | 0.06 | 0.15 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.41B | 4.74B | 5.67B | 6.38B | 6.12B | |
| Average inventory | 8.81B | 9.77B | 11.98B | 14.59B | 17.26B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 131.41 | 148.31 | 130.26 | 134.95 | 101.03 | |
| Days of inventory on hand | 273.26 | 303.37 | 282.61 | 323.08 | 336.58 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.78 | 2.46 | 2.8 | 2.7 | 3.61 | |
| Inventory turnover | 1.34 | 1.2 | 1.29 | 1.13 | 1.08 | |
| ROE | 0.09 | 0.14 | 0.17 | 0.24 | 0.16 | |
| Capex per share | -5.42 | -7.15 | -12.12 | -14.27 | -18.91 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 56.38 | 50.81 | 62.52 | 63.08 | 60.93 | |
| Net income per share | 7.76 | 5.13 | 5.64 | 5.67 | 4.25 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 58.79 | 0 | 57.41 | 0 | |
| Book value per share | 0 | 216.47 | 0 | 227.67 | 0 | |
| Tangible book value per share | 0 | 210.78 | 0 | 221.92 | 0 | |
| Share holders equity per share | 0 | 216.47 | 0 | 227.67 | 0 | |
| Interest debt per share | 0 | 31.95 | 0 | 29.28 | 0 | |
| Market cap | 274.86B | 270.39B | 227.65B | 232.22B | 213.93B | |
| Enterprise value | 0 | 275.71B | 0 | 235.69B | 0 | |
| P/E ratio | 34.89 | 51.91 | 39.78 | 40.34 | 49.59 | |
| Price to sales ratio | 19.21 | 20.97 | 14.36 | 14.51 | 13.84 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 4.92 | 0 | 4.02 | 0 | |
| PTB ratio | 0 | 4.92 | 0 | 4.02 | 0 | |
| EV to sales | 0 | 21.39 | 0 | 14.72 | 0 | |
| Enterprise value over EBITDA | 0 | 123.46 | 0 | 80.18 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.38 | 0 | 0.35 | 0 | |
| Debt to assets | 0 | 0.27 | 0 | 0.26 | 0 | |
| Net debt to EBITDA | 0 | 2.38 | 0 | 1.18 | 0 | |
| Current ratio | 0 | 3.04 | 0 | 3.29 | 0 | |
| Interest coverage | 174.24 | 46.86 | 29.9 | 21.15 | 13.77 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.03 | 0 | 0.03 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 158.12 | 0 | 170.42 | 0 | |
| ROIC | 0 | 0.02 | 0 | 0.02 | 0 | |
| Return on tangible assets | 0 | 0.02 | 0 | 0.02 | 0 | |
| Graham Net | 0 | 13.82 | 0 | 12.99 | 0 | |
| Working capital | 0 | 29.91B | 0 | 31.7B | 0 | |
| Tangible asset value | 0 | 53.48B | 0 | 56.32B | 0 | |
| Net current asset value | 0 | 23.87B | 0 | 25.15B | 0 | |
| Invested capital | 0 | 0.15 | 0 | 0.13 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 117.77 | 0 | 90.25 | 0 | |
| Days of inventory on hand | 0 | 392.34 | 0 | 285.49 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.76 | 0 | 1 | 0 | |
| Inventory turnover | 0 | 0.23 | 0 | 0.32 | 0 | |
| ROE | 0 | 0.02 | 0 | 0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IPCALAB.NS Frequently Asked Questions
What is Ipca Laboratories Limited stock symbol ?
Ipca Laboratories Limited is a IN stock and trading under the symbol IPCALAB.NS
What is Ipca Laboratories Limited stock quote today ?
Ipca Laboratories Limited stock price is $782.85 today.
Is Ipca Laboratories Limited stock public?
Yes, Ipca Laboratories Limited is a publicly traded company.
Company Profile
- Volume Average 290.95K
- Market Capitalization 198.62B
- Employee 15.16K
- CEO Mr. Premchand Godha A.C. A., B. Com., CA
- Headquarters Mumbai,IN
- IPO Date 1994-02-23
-
Website
https://www.ipca.com 
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
